Karlijn Verkerk

Karlijn Verkerk

Auto-generated profile, based on publicly available information

Karlijn Verkerk

Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Utrecht, The Netherlands

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2024 in Acta Oncologica
Verified
Journal Article
Open access
PDF file
SMSoemeya F. Haj Mohammad
Soemeya F. Haj Mohammad
HTHans J.L. Timmer
Hans J.L. Timmer
LZLaurien J. Zeverijn
Laurien J. Zeverijn
BGBirgit S. Geurts
Birgit S. Geurts
ISIlse A.C. Spiekman
Ilse A.C. Spiekman
HGHans Gelderblom
Hans Gelderblom
Background and purpose: The Drug Rediscovery Protocol (DRUP) is a Dutch, pan-cancer, nonrandomized clinical trial that aims to investigate the efficacy and safety of targeted and immunotherapies outside their registered indication in patients with advanced or metastatic cancer. Patients: Patients with advanced or metastatic cancer are eligible when there are no standard of care treatment options left and the tumor possesses a molecular genomic variant for which commercially available anticancer treatment is accessible off-label in DRUP. Clinical benefit is the study’s primary endpoint, characterized by a confirmed objective response or stable disease after at least 16 weeks of treatment. Results: More than 2,500 patients have undergone evaluation, of which over 1,500 have started treatment in DRUP. The overall clinical benefit rate (CBR) remains 33%. The nivolumab cohort for patients with microsatellite instable metastatic tumors proved highly successful with a CBR of 63%, while palbociclib or ribociclib in patients with tumors harboring CDK4/6 pathway alterations showed limited efficacy, with a CBR of 15%. The formation of two European initiatives (PCM4EU and PRIME-ROSE) strives to accelerate implementation and enhance data collection to broaden equitable access to anticancer treatments and gather more evidence. Conclusion: DRUP persists in improving patients access to off-label targeted or immunotherapy in the Netherlands and beyond. The expansion of DRUP-like clinical trials across Europe provides countless opportunities for broadening the horizon of precision oncology.

15 April 2026 in Nature
Verified
Journal Article
Open access
PDF file
KVK. Verkerk
K. Verkerk
ASA. C. Spiekman
A. C. Spiekman
SMS. F. Haj Mohammad
S. F. Haj Mohammad
FVF. A. J. Verbeek
F. A. J. Verbeek
HTH. Timmer
H. Timmer
EVE.E. Voest
E.E. Voest
Anticancer drugs are frequently used off-label for tumours that are genetically similar to the approved indication. However, outcomes are rarely captured systematically, limiting evidence-based decision-making and risking repeated futile treatment. The Drug Rediscovery Protocol (DRUP; ClinicalTrials.gov ID: NCT02925234) prospectively evaluates such off-label use in patients in the Netherlands with advanced solid tumours who lack standard treatment options and harbour actionable genomic alterations1. Here we present results of 1,610 patients who began treatment with 37 different off-label drugs between July 2016 and May 2024 in the DRUP trial. Of these patients, 1,363 were response-evaluable, including 533 (39.1%) with rare cancers. The clinical benefit rate (confirmed response or stable disease for at least 16 weeks) was 34.9% (95% confidence interval, 32.2–37.6) and the objective response rate was 15.7% (95% confidence interval, 13.7–17.9). Median progression-free and overall survival were 3.4 months (95% confidence interval, 2.8–3.5) and 8.2 months (95% confidence interval, 7.6–8.8), respectively. Grade 3 or higher treatment-related adverse events occurred in 28.4% of patients. Notably, evidence generated in DRUP was used for reimbursement decisions by the regulatory bodies in the Netherlands2. Although activity across all tumour–drug combinations was modest, defined molecular subgroups and exceptional responders (7.0%) achieved meaningful benefit. To maximize patient benefit, we recommend that off-label precision medicines should be used only within frameworks that systematically evaluate efficacy and toxicity, support biomarker refinement and enable stepwise assessment toward potential future label expansion. These frameworks should prioritize high-confidence targets, early intervention, regulatory-aligned end-points and international collaboration.

25 September 2025 in Cancer Discovery
Verified
Journal Article
Closed access
IMIris L. Mimpen
Iris L. Mimpen
TBThomas W. Battaglia
Thomas W. Battaglia
MPMiguel Parra-Martinez
Miguel Parra-Martinez
CTCatherine Toner-Bartelds
Catherine Toner-Bartelds
LZLaurien J. Zeverijn
Laurien J. Zeverijn
EVE.E. Voest
E.E. Voest
Studies have identified a link between specific microbiome-derived bacteria and immune checkpoint blockade (ICB) efficacy. However, these species lack consistency across studies, and their immunomodulatory mechanisms remain elusive. To understand the influence of the microbiome on ICB response, we studied its functional capacity. Using pan-cancer metagenomics data from ICB-treated patients, we showed that community-level metabolic pathways are stable across individuals, making them suitable for predicting ICB response. We identified several microbial metabolic processes significantly associated with response, including the methylerythritol 4-phosphate (MEP) pathway, which was associated with response and induced Vδ2 T cell–mediated antitumor responses in patient-derived tumor organoids. In contrast, riboflavin synthesis was associated with ICB resistance, and its intermediates induced mucosal-associated invariant T (MAIT) cell–mediated immune suppression. Moreover, gut metabolomics revealed that high riboflavin levels were linked to worse survival in patients with abundant intratumoral MAIT cells. Collectively, our results highlight the relevance of metabolite-mediated microbiome–immune cell cross-talk. Significance: Microbial metabolic pathways are highly conserved across individuals and therefore offer an opportunity to link the microbiome to immunotherapy efficacy. We identified specific microbial metabolic pathways associated with response to ICB and provided mechanistic insights into the immunomodulatory influence of these pathways on antitumor immunity.

7 January 2025 in ESMO Open
Verified
Journal Article
Open access
KVK. Verkerk
K. Verkerk
LZL.J. Zeverijn
L.J. Zeverijn
JHJ. van de Haar
J. van de Haar
PRP. Roepman
P. Roepman
BGB.S. Geurts
B.S. Geurts
EVE.E. Voest
E.E. Voest
Many patients with cancer exhibit primary or rapid secondary resistance to targeted therapy (TT). We hypothesized that a higher number of altered oncogenic signaling pathways [pathway alteration load (PAL)] would reduce the benefit of TT which only intervenes in one pathway. This hypothesis was tested in the Drug Rediscovery Protocol (DRUP). DRUP is a prospective, pan-cancer, non-randomized clinical trial (NCT02925234) that treats patients with therapy-refractory metastatic cancer and an actionable molecular profile using matched off-label targeted and immunotherapies. All patients treated with TT with available clinical outcomes and whole genome sequencing were included. PAL was determined based on driver gene alterations and correlated with clinical benefit rate (CBR), progression-free survival (PFS) and overall survival (OS). Outcomes were validated in the independent Hartwig Medical database of metastatic cancers. In 154 patients treated with TT, the median PAL was 3. Patients with a PAL below median (n = 60) demonstrated a higher CBR (41.7% versus 25.5%, odds ratio 0.48, P = 0.051), longer PFS [median 4.7 versus 2.9 months, adjusted hazard ratio (aHR) 1.70, P = 0.020] and OS (median 13.7 versus 5.6 months, aHR 3.80, P < 0.001) compared with those with PAL ≥3. Two hundred and fifty-eight patients in the Hartwig database showed similar results for CBR (54.2% versus 36.7%, odds ratio 2.04, P = 0.009) and PFS (7.0 versus 4.2 months, aHR 1.55, P = 0.009). In our population, PAL emerged as a pan-cancer determinant of outcome to TT. Our findings support refined patient selection for TT and highlight the rationale for combinatorial treatment strategies in patients with multiple affected pathways.

1 October 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
KVKarlijn Verkerk
Karlijn Verkerk
TWTijmen J.W.T. van der Wel
Tijmen J.W.T. van der Wel
LZLaurien J. Zeverijn
Laurien J. Zeverijn
BGBirgit S. Geurts
Birgit S. Geurts
ISIlse A.C. Spiekman
Ilse A.C. Spiekman
ALAdrianus de Langen
Adrianus de Langen
Purpose: To provide patients with MET-mutated advanced non–small cell lung cancer (METmut aNSCLC) access to crizotinib, further substantiate evidence of its efficacy and safety in this setting, and find potential biomarkers for nonresponse. Patients and Methods: In the Drug Rediscovery Protocol (NCT0295234), patients with an actionable molecular profile are treated with off-label registered drugs. Both treated and untreated patients with aNSCLC harboring MET exon 14 skipping or other MET mutations received crizotinib 250 mg BID until disease progression or intolerable toxicity. Primary endpoints were clinical benefit [CB: RECIST v1.1 confirmed partial response, complete response (CR), or stable disease ≥16 weeks] and safety. Patients were enrolled using a Simon-like two-stage design, with eight patients in stage I and if ≥1/8 patients had CB, 24 patients in stage II. Whole-genome sequencing and RNA sequencing were performed on baseline biopsies. Results: Between September 2018 and October 2022, 30 patients started treatment, and 24 were response-evaluable after completing ≥1 full treatment cycle. Two patients (8.3%) achieved CR, 13 (54.2%) partial response, and two (8.3%) stable disease. The CB rate was 70.8% [95% confidence interval (CI), 48.9–87.4], and the objective response rate was 62.5% (95% CI, 40.6–81.2). After 21.2-month median follow-up, median duration of response, progression-free survival, and overall survival were 9.3 (95% CI, 6.5–not available), 10.2 (95% CI, 6.0–20.1), and 13.0 months (95% CI, 9.0–not available), respectively. Twenty-three treatment-related grade ≥ 3 adverse events occurred in 12/30 patients (40%), causing treatment discontinuation in three (10%). One patient (achieving CR) had a tyrosine kinase domain mutation (p.H1094Y), and all other patients had MET exon 14 skipping mutations. Conclusions: Crizotinib is a valuable treatment option in METmut aNSCLC.

20 September 2022 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
KVKarlijn Verkerk
Karlijn Verkerk
HOHans-Martin Otten
Hans-Martin Otten
AHAlwin D. R. Huitema
Alwin D. R. Huitema